236 related articles for article (PubMed ID: 26786154)
1. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
2. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
3. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
4. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
5. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
6. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
7. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.
Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV
Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
9. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
10. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
11. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
[TBL] [Abstract][Full Text] [Related]
13. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Lee KT; Jacobs L; Walsh EM; Stearns V; Segal JB
Breast Cancer Res Treat; 2020 Dec; 184(3):965-975. PubMed ID: 32914353
[TBL] [Abstract][Full Text] [Related]
14. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
[TBL] [Abstract][Full Text] [Related]
15. Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Park C; Heo JH; Mehta S; Han S; Spencer JC
Clin Drug Investig; 2023 Mar; 43(3):167-176. PubMed ID: 36740664
[TBL] [Abstract][Full Text] [Related]
16. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
17. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
18. Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.
Wang X; Du XL
Med Oncol; 2015 May; 32(5):154. PubMed ID: 25837434
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
20. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
